Asscociation of risk factors and its bleeding complication for Tenecteplase administered in acute myocardial infarction (AMI)

Metalyse, subgroup of Tenecteplase (TNK-tPA) is a three point mutation of alteplase. It specifically has extended half-life, increased fibrin specificity and patency. In several clinical studies, the single bolus administration of this drug has faster reperfusion, faster clots lysis and longer artery patency 1, 2. It is a triple-combination mutant of tissue plasminogen activator (tPA) developed to overcome some of the limitations of current thrombolytic therapy. This drug works by dissolving blood clots in patient with suspected acute myocardial infarction within six hours of first onset of the symptoms. The administration of this drug within these hours can effectively lyse clots in coronary vessels. Due to the positive evidence, Universiti Kebangsaan Malaysia Medical Centre (UKMMC) Emergency Department has started to use TNK-tPA for ST-elevation myocardial infarction (STEMI) since the past 3 years, replacing streptokinase as the main thrombolytic drug. (Copied from article)